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Cardiol Int 2011;4:1093–5.ReplyWe thank Dr. Palmer and colleagues for commenting on 1 of the
potential important implications of our recently reported ﬁnding
(1). We demonstrated, in healthy volunteers, that ticagrelor
enhanced coronary vasodilatory response to adenosine through
increased sensitivity to adenosine, as shown by a greater area under
the curve for adenosine dose versus coronary blood ﬂow when
ticagrelor was used. A maximum signiﬁcant additive effect was seen
at a submaximal adenosine dose of 80 mg/kg/min. The study was
conducted in healthy volunteers to avoid any confounders, such as
concomitant medications, etc.
Adenosine is a widely used cardiac stress agent for measurement
(e.g., fractional ﬂow reserve [FFR]). However, it has been shown
that maximum hyperemia could not be achieved in all patients
using the standard intravenous adenosine dose of 140 kg/min (2).
Interestingly, the variability in adenosine response could also be
partially explained by the genetic polymorphism in adenosine
receptors (3).
In patients with various risk factors, impaired coronary ﬂow
velocity reserve (CFVR) has been reported and has also shown
strong predictive values for future cardiovascular outcomes (4).
Thus, it is conceivable that ticagrelor may also enhance the
maximum hyperemic response in patients with impaired CFVR
through increased hyperemic ﬂow velocity response. If that is the
case, this will lead to an increased drop in pressure over a certain
stenosis, and thereby, lower the FFR value. As correctly pointed out
by Palmer et al., this will likely improve the accuracy and consis-
tency of FFR measurements in the future.
Finally, because our data were generated in healthy volunteers,
the concept still needs to be demonstrated in patients with coronary
artery disease. Thus, more studies are warranted to prove the
hypothesis raised by Palmer et al.*Li-Ming Gan, MD, PhD
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Cardiol Img 2012;5:1079–85.Choosing Troponin Immunoassays
in a World of Limited Resources
We read with interest the report by Korley and Jaffe (1), who
elaborated several critical issues as a means of educating clinicians
about cardiac troponin immunoassays. Although the investigators
should be praised for their effort to synthesize and emphasize the
leading problems and drawbacks, another important issue engages
the minds of clinicians and laboratory professionals. There is open
debate about the different analytical and clinical performance of the
different troponin immunoassays (2,3). Because of the ongoing
economic crisis and the increasing pressure placed on clinical
laboratories to conserve economic and human resources, there is
a widespread phenomenon of merging of existing clinical labora-
tories into larger ones, accompanied by consolidation of different
tests within multitasking analytical platforms (4). The in vitro
diagnostic industry is continuously developing and marketing
integrated instrumentation, where the consolidation of most clin-
ical chemistry and a variety of immunochemistry tests is indeed an
efﬁcient and cost-effective solution in a world of limited resources.
What some clinicians often ignore is that the procedures for
purchasing instrumentations and reagents in clinical laboratories
are challenging and increasingly involve a large number of tests
rather than individual parameters (4). Regardless of its unques-
tionable clinical value for cardiologists and emergency physicians,
troponin testing is only a minor part of the game in the context of
a large tender for laboratory equipment, so that the acquisition of
dedicated instrumentation to measure only troponin is becoming
problematic, especially in some European countries. In this
perspective, the question as to whether troponin T may be better
than troponin I for identifying myocardial injury, and even whether
one troponin I immunoassay may perform better than another for
diagnosing myocardial infarction, will become virtually academic in
the foreseeable future, provided that the methods are straightfor-
ward and fulﬁll basic criteria of analytical quality (5).
All that said, a reasonable solution can be developed. Supported by
science, rather than the market, the in vitro diagnostic companies
should be encouraged to reach a formal agreement to standardize
their immunoassays around 1 molecule (either cardiac troponin I or
T) and, even more important, on immunoassays calibrated using an
identical reference material and containing a cocktail of antibodies
that recognize the same andmore analytically suitable epitopes of the
proteins. This solution would also be more effective than continuing
to pursue a challenging harmonization or an unlikely standardization
of the different troponin I methods (6).*Giuseppe Lippi, MD
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